Literature DB >> 12077721

Pharmacogenomics in cardiovascular diseases.

Debabrata Mukherjee1, Eric J Topol.   

Abstract

Considerable heterogeneity exists in the way individuals respond to medications, in terms of both efficacy and safety. Inherited differences in the absorption, metabolism, excretion, and target for drug therapy have important effects on drug efficacy and safety. Pharmacogenomics aims to discover new therapeutic targets and understand genetic polymorphisms that determine the safety and efficacy of medications. The goal of pharmaco-genomics is customization of drug therapy with administration of a medication in an optimum dose that will be safe and effective with reduction in morbidity and mortality. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12077721     DOI: 10.1053/pcad.2002.123467

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  6 in total

1.  Personalized medicine: Time for one-person trials.

Authors:  Nicholas J Schork
Journal:  Nature       Date:  2015-04-30       Impact factor: 49.962

Review 2.  Aspirin resistance - does it clinically matter?

Authors:  Karsten Schrör; T Hohlfeld; A-A Weber
Journal:  Clin Res Cardiol       Date:  2006-08-16       Impact factor: 5.460

3.  Genotype-based risk and pharmacogenetic sampling in clinical trials.

Authors:  Nicholas J Schork; Eric J Topol
Journal:  J Biopharm Stat       Date:  2010-03       Impact factor: 1.051

Review 4.  Genomic translational research: Paving the way to individualized cardiac functional analyses and personalized cardiology.

Authors:  Ares Pasipoularides
Journal:  Int J Cardiol       Date:  2016-12-21       Impact factor: 4.164

Review 5.  Classification of advanced stages of Parkinson's disease: translation into stratified treatments.

Authors:  Rejko Krüger; Jochen Klucken; Daniel Weiss; Lars Tönges; Pierre Kolber; Stefan Unterecker; Michael Lorrain; Horst Baas; Thomas Müller; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2017-03-24       Impact factor: 3.575

6.  The single-cell eQTLGen consortium.

Authors:  Mgp van der Wijst; D H de Vries; H E Groot; G Trynka; C C Hon; M J Bonder; O Stegle; M C Nawijn; Y Idaghdour; P van der Harst; C J Ye; J Powell; F J Theis; A Mahfouz; M Heinig; L Franke
Journal:  Elife       Date:  2020-03-09       Impact factor: 8.140

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.